AVEO Pharmaceuticals Enters into Worldwide License Agreement with Centocor Ortho Biotech to Develop and Commercialize RON-Targeted Antibodies.
Linked as:
Extract
AVEO Pharmaceuticals Enters into Worldwide License Agreement with Centocor Ortho Biotech to Develop and Commercialize RON-Targeted Antibodies.
CAMBRIDGE, Mass. -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced it has entered into an exclusive license agreement with Centocor Ortho Biotech Inc. for the worldwide development and commercialization of AVEO's internally-discovered antibodies targeting the RON (Recepteur d'Origine Nantais) receptor. The RON pathway is be...
See the full content of this document
Sponsored links
